Navigation Links
Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
Date:1/25/2010

PRINCETON, N.J., Jan. 25 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Steven Leventer, Ph.D. has been appointed Vice President, Clinical Research Neuroscience.

"We are very pleased to have Steve join PharmaNet Development Group," commented Dalvir Gill, Chief Operating Officer, Late Stage Development. "Steve is a recognized expert in the fields of clinical trial design and clinical development planning. His combination of neuroscience expertise and dedication to efficiency and quality provides the right complement to our existing organization."

Dr. Leventer has over twenty years of experience in all phases of drug development. He has spent most of his career leading clinical teams at large global pharmaceutical and contract research organizations in the development of therapeutics for Alzheimer's disease, schizophrenia, depression and other central nervous system diseases. He was trained as a neurochemist and has had post-doctoral fellowships and faculty appointments at the University of Texas, Western Psychiatric Institute and Clinic, and Loyola University Stritch School of Medicine.  

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  


    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    Email: ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.

RELATED LINKS
http://www.pharmanet.com

'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
2. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
3. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
4. CooperVision Adds Global Professional Relations Role; Richard Clompus Joins Company as Vice President
5. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
6. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
7. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
8. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
9. PFC Pharma Joins DATATRAKs CRO Connect Program
10. William Cork Joins Fenwal as Chief Technology Officer
11. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):